Here's Where Things Went Wrong for Core Laboratories N.V. in 2017
Shares of Core Labs (NYSE: CLB) are down a disappointing 17.8% this year, vastly underperforming oil prices and the red-hot stock market. That decline also came despite the fact that its financial results have improved, with revenue through the third quarter up 9.6% versus the year-ago period while earnings have rebounded 25.2% over that same time frame. Instead, what seems to be weighing on the stock is that the company promised even better results but failed to deliver because the oil market didn't recover as briskly as it anticipated.
Here's a look at what went wrong this year and why 2018 looks like it should be a better year.
Image source: Getty Images.
Source: Fool.com
Core Laboratories Inc. Aktie
15,00 €
0,67 %
Leichtes Sell-Übergewicht bei Core Laboratories Inc. mit 3 Sell- gegenüber 0 Buy-Einschätzungen.
Ein negatives, wenn auch nicht starkes, Potenzial für Core Laboratories Inc. mit einem Kursziel von 14 € im Vergleich zu 15.0 €.
